Please assess the completion status of the following clinical trial:

Trial Title: Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Key Inclusion Criteria:~* Subjects must be able to understand and agree to comply with the prescribed dosing regimens and procedures, report for regularly scheduled study visits, and reliably communicate with study personnel about adverse events and concomitant medications~* Subjects chronically infected with hepatitis C virus (HCV) genotype 3~* Subjects who are HCV treatment-naive~* Subjects who are HCV treatment-experienced (previous exposure to non-structural 5A inhibitors is prohibited)~* HCV RNA ≥10,000 IU/mL at screening~Key Exclusion Criteria:~* HCV Genotypes other than genotype-3 infection; mixed genotype infections are not permitted~* Liver or any other organ transplant (including hematopoietic stem cell transplants) other than cornea and hair~* Current or known history of cancer (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to screening~* Documented or suspected hepatocellular carcinoma, as evidenced by previously obtained imaging studies or liver biopsy (or on a screening imaging study/liver biopsy if this was performed)~* Evidence of decompensated liver disease including, but not limited to, radiologic criteria, a history or presence of ascites, bleeding varices, or hepatic encephalopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A1:Daclatasvir + Sofosbuvir in treatment-naive subjects (Type: EXPERIMENTAL): Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks
- A2:Daclatasvir + Sofosbuvir in treatment-experienced subjects (Type: EXPERIMENTAL): Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).